Micro-Tech Endoscopy’s acquisition of global distribution rights for key Conmed GI products isn’t just a portfolio expansion—it’s a strategic consolidation of control across the endoscopy value chain.
By bringing Duraclip (hemostasis) and Precisor/Optibite (biopsy) fully in-house, Micro-Tech is moving from being a behind-the-scenes manufacturer to a frontline commercial player with a more complete procedural toolkit.
The timing is equally telling. Conmed’s exit from the GI segment reflects a broader reality in medtech: fragmented portfolios are giving way to focused, category-dominant players. In contrast, Micro-Tech is doubling down—building an integrated offering that spans closure, biopsy, and visualization.
For providers, especially ASCs, this signals a shift toward vendor consolidation and bundled solutions—where fewer companies aim to cover more of the procedure.